CUE Cue Biopharma, Inc. Insider Trading

Director Sarraf Pasha buys 323,857 shares at $0.31 blended avg (total $99,747.26) as CUE trades 80.7% below 52-week high.

Sarraf Pasha executed 5 separate purchases on 2025-12-30 totaling 323,857 shares for $99,747.26 at a blended average price of $0.31, bringing his holdings from 0 to 323,857 shares. The timing is notable: CUE's stock is trading at $10.12, which is -80.7% from the 52-week high of $52.50 and has declined -39.9% over the prior 30 days and -53.7% over the prior 90 days. The company faces profitability challenges with net income of $-7,448,000 in the latest quarter despite revenue growth of +69.2% year-over-year, and holds a market cap of $796,825,888.32. This substantial new position by a director during a steep drawdown warrants attention to whether it reflects confidence in valuation at depressed levels or other factors driving the transaction.

CUE CEO Daniel Passeri bought 30,000 shares at $1.03 on 2024-12-16; holds 164,578 shares post-transaction despite stock -65.5% from 52-week high.

CEO Daniel Passeri purchased 30,000 shares at $1.03, increasing his holdings to 164,578 shares (+22.3% expansion). The purchase occurred at a steep discount: the current price of $32.10 is -65.5% from the 52-week high of $93.00, and the stock is up +89.4% over the prior 90 days from its lows. Passeri's prior buy at CUE on 2023-08-14 exhibited strong 90-day post-purchase returns (+2323.1%), demonstrating a historical pattern of well-timed entry points at this ticker. The company reported quarterly revenue of $3,336,000.00 with net income of $-8,660,000.00, indicating ongoing losses, though annual revenue growth was +340.9% year-over-year. The combination of a large discretionary accumulation at depressed absolute prices, paired with the insider's demonstrated track record of well-timed purchases at CUE and a company in hypergrowth mode despite current unprofitability, merits investor attention to the conviction signal and underlying business trajectory.